Saturday, September 18, 2021

Sorrento moves to buy delayed burst release naltrexone drug

Sorrento Therapeutics has moved to buy a delayed burst release formulation of low-dose naltrexone from Aardvark Therapeutics. The formulation is set to move into a phase 2 fibromyalgia clinical trial this year.

Naltrexone is an opioid-receptor antagonist used in 25-mg to 50-mg daily doses in the management of alcohol and opioid dependence. Aardvark has identified an opportunity to modify the release of the molecule to unlock opportunities in indications including chronic pain, fibromyalgia and lasting effects of coronavirus infection, a condition known colloquially as long COVID.  

Interest in the indications is underpinned by evidence that low-dose naltrexone, typically 4.5 mg a day, has properties such as analgesia and anti-inflammatory effects that are not seen when it is given at higher doses. 

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.

Sorrento, through its majority-owned subsidiary Scilex Holding Company, is now poised to help find out whether Aardvark’s delayed burst release formulation of low-dose naltrexone, ARD-301, can build on signs of efficacy seen in other studies. Sorrento and Scilex have entered into an exclusive licensing term sheet with Aardvark to acquire ARD-301.

Once the definitive agreement is executed, Scilex and Aardvark plan to collaborate on a phase 2 trial in fibromyalgia, an indication in which there remains unmet needs despite the availability of several treatment options. Some fibromyalgia patients take opioids to manage the pain. ARD-301 may offer an alternative to opioids. 

Sorrento and Scilex see multiple other therapeutic opportunities for ARD-301 and are planning to run phase 2 clinical trials this year. Long COVID is on the list of target indications. Understanding of long COVID, which is characterized by the persistence of a range of symptoms long after the infection has cleared, remains limited, but there is a potentially significant market given how many people have contracted the coronavirus.   

Source link

Latest Articles

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...

Understand Key Account Management

INTRODUCTION: Key Account Management is the essential showcasing approach that gives a successful, useful, and rather basic technique for...

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...